In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Insmed, with a price target of $193.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ritu Baral has given her Buy rating due to a combination of factors related to Insmed’s promising clinical trial results. The company presented impressive Phase 2 data for its TPIP treatment for pulmonary arterial hypertension (PAH) at the European Respiratory Society meeting, which showed significant improvements in hemodynamic parameters. These results suggest a positive impact on heart function and support the pulmonary selectivity of TPIP.
Furthermore, the data included statistically significant reductions in pulmonary vascular resistance and improvements in the six-minute walk distance and NT-proBNP levels, which are critical indicators of PAH treatment efficacy. The presentation also highlighted improvements in various cardiopulmonary hemodynamic parameters, reinforcing the potential of TPIP as a treatment. Insmed’s plans to expand TPIP development into idiopathic pulmonary fibrosis and the anticipated start of a Phase 3 trial in 2026 further bolster the stock’s potential, leading to an increased price target based on expected future revenue.
According to TipRanks, Baral is a 5-star analyst with an average return of 18.7% and a 52.92% success rate. Baral covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Krystal Biotech, and Insmed.
In another report released today, Evercore ISI also maintained a Buy rating on the stock with a $180.00 price target.